Literature DB >> 10450926

Structural requirements for alkylglycoside-type renal targeting vector.

K Suzuki1, T Ando, H Susaki, K Mimori, S Nakabayashi, Y Sugiyama.   

Abstract

PURPOSE: We have previously shown Glc-S-C7-Me (octyl beta-D-thioglucoside) exhibits renal targeting potential in vivo in addition to its specific binding to the renal membrane fraction in vitro. Thus, "alkylglycoside" is considered to be a novel targeting vector for the kidney (1,2). The present study is designed to clarify the structural requirements for alkylglycoside as a renal targeting vector.
METHODS: Inhibitory effects of various sugars and glycosides on 3H-Glc-S-C7-Me binding to the kidney membrane fraction were evaluated by a centrifugation method.
RESULTS: As far as the sugar moiety is concerned, no other sugars except D-aldohexose and D-aldohexose derivatives (containing F, S, and N) showed greater inhibition than D-glucose. Therefore, octylthio derivatives of various D-aldohexose were prepared and their inhibitory effects were investigated. The following findings were obtained: Equatorial OH at 4 position is essential; OH at 2 position can have either orientation or be deleted. As far as the alkyl moiety is concerned, the length, branching and electrical environment in the region of the glycoside bond are important; aromatic structures can substitute for the alkyl portion; the preferred glycoside bonding atom is as follows: S > NH > O.
CONCLUSIONS: The structural requirements for the renal targeting vector have been identified to be as follows: a hydrophobic group (alkyl chain or aromatic ring) should be introduced to a sugar (D-glucose, D-mannose, or 2-deoxy-D-glucose) via a beta-glycoside binding atom (S > NH > O).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450926     DOI: 10.1023/a:1018979515073

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

Review 1.  Receptor-mediated endocytosis of macromolecular conjugates in selective drug delivery.

Authors:  S K Basu
Journal:  Biochem Pharmacol       Date:  1990-11-01       Impact factor: 5.858

2.  Renal drug targeting using a vector "alkylglycoside".

Authors:  K Suzuki; H Susaki; S Okuno; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

3.  Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo.

Authors:  M Haas; A C Kluppel; E S Wartna; F Moolenaar; D K Meijer; P E de Jong; D de Zeeuw
Journal:  Kidney Int       Date:  1997-12       Impact factor: 10.612

Review 4.  Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes.

Authors:  B Thorens
Journal:  Am J Physiol       Date:  1996-04

5.  Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme.

Authors:  R J Kok; M Haas; F Moolenaar; D de Zeeuw; D K Meijer
Journal:  Ren Fail       Date:  1998-03       Impact factor: 2.606

6.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions.

Authors:  N Kasahara; A M Dozy; Y W Kan
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

7.  Synthesis of artificial glycoconjugates of arginine-vasopressin and their antidiuretic activities.

Authors:  H Susaki; K Suzuki; M Ikeda; H Yamada; H K Watanabe
Journal:  Chem Pharm Bull (Tokyo)       Date:  1994-10       Impact factor: 1.645

8.  Renal selective N-acetyl-L-gamma-glutamyl prodrugs: studies on the selectivity of some model prodrugs.

Authors:  J C Drieman; H H Thijssen; H A Struyker-Boudier
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

9.  Molecular mechanisms of novel antidiuretic antagonists: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney.

Authors:  F L Stassen; R W Erickson; W F Huffman; J Stefankiewicz; L Sulat; V D Wiebelhaus
Journal:  J Pharmacol Exp Ther       Date:  1982-10       Impact factor: 4.030

10.  Specific renal delivery of sugar-modified low-molecular-weight peptides.

Authors:  K Suzuki; H Susaki; S Okuno; H Yamada; H K Watanabe; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

View more
  2 in total

1.  Detection of the membrane protein recognized by the kidney-specific alkylglucoside vector.

Authors:  Y Watanabe; H Suzuki; K Suzuki; T Ando; S Nakabayashi; Y Sugiyama
Journal:  Pharm Res       Date:  2000-01       Impact factor: 4.200

2.  Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes.

Authors:  Francisco Castaneda; Antje Burse; Wilhelm Boland; Rolf K-H Kinne
Journal:  Int J Med Sci       Date:  2007-05-05       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.